Our staff is glad to announce the release of our first COVID-19 vaccine that goes under the title mRNA-1273. We started our work right after the Chinese scientists revealed the genetic sequence of this type of coronavirus. We succeeded in the development of the prototype that was ready in winter 2020. After all the necessary tests and clinical trials that involved 30,000 participants aged between 18 and 71+.
The participants pertained to different ethnic groups, which shows that the vaccine is effective irrespective of such demographic features as ethnicity or age. The proven efficacy of the vaccine is more than 94%. The most vulnerable groups can finally feel safe as we have the medicine to protect them. Older people, patients with chronic conditions, healthcare professionals and other individuals who can be exposed to infection can be the front-line receivers of the vaccine.
We all remember the shock of the first months of the pandemic, and the new infection made people see the vulnerability of healthcare systems worldwide. The outcomes of the disease may be serious for many people. Older individuals, as well as patients with chronic disorders irrespective of their age, tend to develop severe health conditions that can be difficult to cure. In many cases, the virus leaves no chances to patients, and we know the sad statistics of millions of deceased due to COVID-19. The devastating effects of the disorder on many patients’ health and their quality of life are also well-known. Therefore, it is pivotal to prevent rather than try to treat the new infectious disease. We offer our vaccine as an effective preventive measure that can save lives and improve people’s quality of life.
mRNA-1273 is created on the basis of the genetic code of the virus, which makes it an effective instrument against the infection. One of the benefits of our vaccine is its usability as it is stable at 2-8 degrees Celsius for 30 days. This stability is critical since standard medical and even home refrigerators can sustain its stability, which can be critical for rural settings or lower-income communities. Any healthcare facility in the USA, as well as beyond its borders, can become a place where a person can be vaccinated. No specific equipment is necessary for transportation and storage. Hence, the cost of vaccination is also reduced significantly.
Importantly, MODERNA implemented trials involving the most vulnerable groups in collaboration with the FDA and NIH. These institutions provided favorable feedback regarding the use of the vaccine and will initiate Emergency Use Authorization. The importance of the urgent application of an effective vaccine is critical for the USA and worldwide. We are ready to produce our vaccine that can satisfy the needs of the United States and other countries. MODERNA has the necessary facilities and collaborates with reliable partners, producing high-quality products at the necessary pace.
The current lockdowns and associated economic constraints are measures that proved their effectiveness at a very high cost. Governments and authorities can control the spread of the infection by forcing people to stay home, shaping their habits and lifestyles. Economies of all countries have experienced recessions and major shocks due to these measures. mRNA-1273 is a much safer and more cost-effective method to combat the COVID-19 pandemic.
People do not need to be isolated or run the risk of being infected. Our vaccine will also reduce the death rate due to COVID-19 to a minimum. The vaccine is safe for people of all ages, ethnic groups, and other demographic characteristics, so we are proud to state that mRNA-1273 is a global vaccine. We are happy to announce that we have found the cure that will help humanity to continue its development.